Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
This is a mechanism no approved drug currently uses Phase 2 trials showed up to 24% body weight reduction over 48 weeks, meaningfully exceeding tirzepatide and semaglutide outcomes Phase 3 trials are currently underway
Injectable GHK-Cu reaches follicle-depth tissue at 10 to 20 times the concentration of topical serums, making it more effective for moderate-to-advanced loss
Multi-vial sealed boxes typically priced as the value-per-mg leader on our catalog
The global market for weight-loss drugs is expected to reach $150 billion by 2035, according to research by Morgan Stanley, an increase from a previous forecast of $105 billion
This "protein-first" approach, adapted from bariatric nutrition principles, may help maintain lean mass during weight loss interventions
US$ 25.40
US$ 27.54
US$ 24.73
US$ 26.60
US$ 25.01
US$ 20.72
US$ 26.16
US$ 29.56
US$ 21.48
US$ 24.95
US$ 27.94
US$ 26.67
US$ 29.83
US$ 23.29
